Enhertu

Enhertu (Trastuzumab Deruxtecan) is an advanced intravenous medication used for targeted therapy. It combines a monoclonal antibody with a cytotoxic agent to support cancer treatment.

Enhertu is primarily used in the treatment of certain types of cancer, particularly those that express the HER2 protein. This medication is designed to target and destroy cancer cells while minimizing damage to healthy cells. Patients often wonder, 'What is Enhertu used for?' It is typically prescribed for advanced or metastatic cancers that have progressed after other treatments.

Common effects of Enhertu may include fatigue, nausea, and hair loss. Some patients may experience more severe side effects, such as decreased blood cell counts or damage to the heart. It is important to discuss any unusual symptoms with a healthcare provider.

Enhertu should be handled with care and administered by healthcare professionals. Patients should be monitored regularly for signs of adverse reactions. Pregnant women or those planning to become pregnant should consult their doctor before starting this medication.

Enhertu may interact with other medications, including those that suppress the immune system or affect blood cell production. It is important to inform healthcare providers about all current medications to avoid potential interactions.